Dr. Torsten Falk is an associate professor of neurology and pharmacology at The University of Arizona. He is director of the preclinical Parkinson's disease laboratory and received his PhD from the University of Hamburg, Germany. Dr. Falk has authored more than 35 peer-reviewed journal publications (h-index: 19, i-10-index: 29) and more than 140 peer-reviewed abstracts and conference presentations. He holds two patents, and his work has led to ongoing clinical trials testing a novel treatment for levodopa-induced dyskinesias. His work focuses on preclinical models to test novel pharmacological treatments for levodopa-induced dyskinesias, a major side effect of Parkinson’s disease (PD) treatment, and to develop glycopeptides for the treatment of PD. He is co-founder of Teleport Pharmaceuticals, LLC, a member of the grant review committee for the Parkinson's Foundation, a standing member of the NIH CNNT study section and an ad hoc reviewer for MJFF and the Parkinson’s UK Foundation.